Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole
Status:
Completed
Trial end date:
2019-08-05
Target enrollment:
Participant gender:
Summary
Characterize the safety, tolerability, ECG effects, pharmacokinetics and immunogenicity of
anetumab ravtansine given as single agent and after inhibition of CYP3A4 and P-gp by
concomitant administration of itraconazole in subjects with mesothelin-expressing advanced
solid cancers